Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Patrick Manchester
Patrick E. Manchester
Partner
Washington +1 202 662 5570 pmanchester@cov.com Download V-card

Patrick Manchester represents a variety of clients in the purchase and sale of public and private companies and their assets. His experience includes helping clients navigate all aspects of asset and stock acquisitions, public and private mergers, carve-out divestitures, and cross-border transactions.

Mr. Manchester’s practice is primarily focused on the life sciences industry, and he has represented a number of major life sciences companies on both the buy-side and sell-side of M&A transactions. He has also represented clients in a number of other industries, as well as sponsors and target companies in private equity transactions covering a wide range of industries.

  • Bacardi in its acquisition of Patrón Spirits International AG and its PATRÓN® brand, the world’s top-selling ultra-premium tequila, from John Paul DeJoria, a founder of Patrón, in a deal valuing the company at $5.1 billion. 
  • Boehringer Ingelheim in a series of antitrust-driven divestitures of a portfolio of animal health products and a manufacturing facility in connection with Boehringer’s acquisition of Merial (Sanofi’s animal health business), and in the $300 million sale of its Bedford Laboratories generic sterile injectables business to Hikma Pharmaceuticals plc.
  • TE Connectivity Ltd. in the $325 million sale of its subsea communications business unit to an affiliate of Cerberus Capital Management, L.P. 
  • Allergan plc (formerly Forest Laboratories) in its acquisitions of Anterios, Inc. and Oculeve, Inc., its $1.1 billion acquisition of Furiex Pharmaceuticals, Inc. and its $1.2 billion acquisition of Clinical Data, Inc.
  • Stryker Corporation in its acquisition of the CareFusion vertebral compression fracture product portfolio from Becton, Dickinson and Company, and in its acquisition of Muka Metal, A.S., a company based in Kayseri, Turkey that sells hospital beds, stretchers and related patient room furniture and accessories.   
  • Strategic Resources International, Inc. in its sale to Peraton Corporation.
  • ITOCHU Corporation and ITOCHU International Inc. in the sale of PrimeSource Building Products, Inc. to an affiliate of Platinum Equity.
  • Gilde Equity Management (a Netherlands-based private equity sponsor) in its acquisition of OnGuard Industries, a U.S.-based manufacturer of protective footwear and clothing for agricultural and industrial applications, from Ansell Limited (an Australian listed company).
  • Medimetriks Pharmaceuticals, Inc. in the sale of its US rights to XepiTM, a topical product for the treatment of impetigo, to Cutanea Life Sciences, Inc.
  • U.S.-based private equity funds in their leveraged buyout of a family of Canadian mortgage servicing and origination companies.
  • A major global healthcare company in the sale of its healthcare antisepsis solutions business in India, East Asia and Oceania.
  • Salix Pharmaceuticals, Ltd. in its $2.6 billion acquisition of Santarus, Inc.
  • Omthera Pharmaceuticals, Inc. in its acquisition by AstraZeneca for $323 million in upfront consideration and up to $120 million in contingent consideration.
  • Resource Capital Corp. in the restructuring of its investment in Leaf Commercial Capital, Inc. (LEAF), undertaken in connection with a $50 million growth equity investment in LEAF by Eos Partners, L.P. and its affiliates.
  • Bristol-Myers Squibb Company in its acquisition of Amira Pharmaceuticals, Inc. for $325 million in upfront consideration and up to $150 million in contingent consideration.
  • Charlesbank Capital Partners in its acquisition of Peacock Engineering Company, LLC.
  • King Pharmaceuticals, Inc. in its $3.6 billion acquisition by Pfizer, Inc.   
  • A major global pharmaceutical company in the restructuring of its Latin American subsidiaries.

Previous Experience

  • Mercatus Center, George Mason University, Research Associate (2007)
  • New York Super Lawyers, Mergers & Acquisitions “Rising Star” (2014-2016)
  • Washington, DC Super Lawyers, Mergers & Acquisitions “Rising Star” (2018)